No meaningful population-level survival improvement seen from 1990 to 2023
FRIDAY, June 12, 2026 (HealthDay News) — Mesothelioma deaths and diagnoses continue to rise in the United States despite regulation limiting the use of asbestos, according to a study published online June 11 in JCO Global Oncology.
Kyle Edwards, from the University of Miami Miller School of Medicine, and colleagues evaluated the U.S. population-level burden of mesothelioma. The analysis included national- and state-level data (1990 to 2023) from the Global Burden of Disease database.
The researchers found that nationally, age-standardized incidence rates (ASIR) declined 33 percent (0.64 to 0.43 per 100,000) and age-standardized mortality rates (ASMR) declined 31 percent (0.60 to 0.41) from 1990 to 2023. Even steeper reductions were seen among men (ASIR, −42 percent; ASMR, −41 percent) versus women (ASIR, −7 percent; ASMR, −8 percent). There was no meaningful population-level survival improvement observed, with mortality-to-incidence ratios rising from 0.93 to 0.95 overall and from 0.95 to 0.98 among men. In 2023, occupational asbestos exposure accounted for 95.7 percent of deaths. There was a 40 percent decline in age-standardized disability-adjusted life-year (DALY) rates, although absolute DALYs increased 14 percent. The highest ASIRs and ASMRs were seen in Maine, Alaska, Washington state, and Minnesota.
“Declining rates don”t necessarily mean fewer lives affected,” Edwards said in a statement. “When you look at absolute numbers and disability, mesothelioma remains a substantial public health problem.”
Several authors disclosed ties to the pharmaceutical and biotechnology industries.
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children
Fractional Exhaled Nitric Oxide Elevated in Pediatric Chest Tightness Variant Asthma
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths
Recommendations Updated for Radiation Therapy in Pancreatic Cancer
Cancer Risk ID"d for Asian American, NHPI Population
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Sleep Disturbances, Duration Linked to Working Life Expectancy